Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial

DOI: 10.1101/2024.02.02.24302227 Publication Date: 2024-02-06T23:25:10Z
ABSTRACT
Abstract We report the short- and long-term results of SOLIDARITY Finland on mortality other patient-important outcomes in patients hospitalised for COVID-19. Between 08/2021 03/2023, we randomised 156 15 hospitals. In imatinib group, 7.2% had died at 30 days 13.3% 1 year standard care group 4.1% 8.3% (adjusted HR 1.09, 95% CI 0.23–5.07). a meta-analysis trials versus (n=732), allocation to was associated with risk ratio 0.73 (95% 0.32–1.63). At 1-year, self-reported recovery occurred 79.0% 88.3% (RR 0.91, 0.78-1.06). Of 21 potential long COVID symptoms, often reported moderate or major bother from fatigue (24%), sleeping problems (19%) memory difficulties (17%). found no convincing difference between groups quality life symptom outcomes. The evidence raises serious doubts regarding benefit reducing mortality, improving recovery, preventing symptoms when given
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (0)